newsfilter
← Latest News
ACCESS Newswire·

Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

  • Sunshine Biopharma Inc. (NASDAQ: SBFM) received U.S. Patent No. 12,624,066 B2 from the USPTO on May 29, 2026.
  • The patent covers proprietary small molecule inhibitors designed to treat coronavirus infections by targeting the PLpro viral enzyme.
  • This technology aims to remain effective against future viral mutations by targeting a highly conserved viral function.
  • CEO Dr. Steve Slilaty stated the patent validates the company's strategy to address both current variants and potential future threats.
  • The patented compounds are ready for GLP studies, a prerequisite step before entering clinical trials.
  • Sunshine Biopharma currently markets 60 generic prescription drugs in Canada with 12 additional launches scheduled for late 2026.
  • The company's proprietary pipeline includes K1.1 mRNA for liver cancer and the PLpro protease inhibitor for SARS Coronavirus infections.